A development stage biopharmaceutical company that develops a fibrin-derived peptide
for the treatment of diseases related to vascular leakage
e.g., ARDS in patients
with underlying COVID-19 infection.
More soon...
SIRS Therapeutics GmbH
Türkenstraße 5
80333 München
Handelsregister: München 240453
VAT-ID: DE331612834
Kontakt: info@sirs-therapeutics.com